biotickrImmix Biopharma Inc
The IMMX stock trades on Nasdaq All Markets
Company Description
ImmixBio was founded in 2012 by a visionary physician/scientist, a world-renown pharmacology expert, a seasoned biotechnology patent attorney and an impact-driven founding family office. We are developing an entirely new class of Tissue-Specific Therapeutics, or TSTx, which we believe will replace first-line therapies across a multitude of cancer indications. At Immix Biopharma, our SMARxT Tissue-Specific Platform produces Tissue-Specific Therapies (TSTx), which in cancer target all 3 components of the TME simultaneously, severing the critical lifelines between the tumor and its metabolic support using TME Normalization Technology. In immuno-dysregulated diseases, our Immune Normalization Technology halts the self-sustaining feed-forward loop propagated among 3 key cell-types in inflammatory bowel disease, addressing the root cause of inflammatory pathologies. Our mission is to create an entirely new class Tissue-Specific Therapeutics (TSTx) that personalize treatment to address the complexity of diseases in every patient, starting with oncology & immuno-dysregulated diseases.
Technology
At Immix Biopharma, our SMARxT Tissue-Specific Platform produces Tissue-Specific Therapies (TSTx), which in cancer target all 3 components of the TME simultaneously, severing the critical lifelines between the tumor and its metabolic support using TME Normalization Technology. In immuno-dysregulated diseases, our Immune Normalization Technology halts the self-sustaining feed-forward loop propagated among 3 key cell-types in inflammatory bowel disease, addressing the root cause of inflammatory pathologies. Our mission is to create an entirely new class Tissue-Specific Therapeutics (TSTx) that personalize treatment to address the complexity of diseases in every patient, starting with oncology & immuno-dysregulated diseases.
Drug Pipeline
Source: Immix Biopharma Inc - 20221121
Asset
Indication
Pre-Clinical
Ph1
Ph2
Ph3
Reg/Com
Phase
iMX-110
Soft Tissue Sarcoma
Phase 2
Solid Tumors
Preclinical
iMX-111
Colorectal Cancer
Preclinical
iMX-120
Inflammatory Bowel Disease
Preclinical
Conversation
0 following
1 Comments on IMMX stock
Newest
Immix Biopharm is aiming to supplant existing first line cancer treatments with the development of Tissue-Specific Therapeutics. Designations granted by the FDA are helping to expedite development. After reviewing pre-clinical trial data for IMX-110 and knowing the current unmet need for these types of treatments there is a place in the market for IMX-110 provided current ongoing trials show positive data readouts.
Should IMX-110 reach commercialization the priority review voucher granted by the FDA has an estimated market value in excess of $90 million. This could be sold or utilized for another candidate. Current cash reserves are stated to last the next year minimizing risk of dilution while waiting for additional pre-clinical data for other pipeline candidates and results from the IMX-110 Phase 1b/2a clinical trials which are ongoing.
Positive data in the oncology space can cause massive runs in the stock price of a company, especially one with a low float. The company is also focused on minimizing overall expenses as discussed during IMMX milestone day in April of 2022. Overall, the risk here is heavily mitigated, pre-clinical data looks promising, and the massive oncology market attract partners easily with positive data.
I will keep my eyes on this one!